Search research articles
Contact Us
Filters
Showing results (61-70 of 88) with videos related to
Page
of 9
Sort By:
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
April 28, 2021
Targeting myosin 1c inhibits murine hepatic fibrogenesis
Ehtesham Arif, Cindy Wang, Marzena K Swiderska-Syn, et al.
Ejhaem
|
August 21, 2023
SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731
Caitlin W Elgarten, John A Kairalla, Joel C Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2020
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Sumit Gupta, Cindy Wang, Elizabeth A Raetz, et al.
Pediatric Blood & Cancer
|
June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Genome Medicine
|
August 8, 2025
Building digital histology models of transcriptional tumor programs with generative deep learning for pathology-based precision medicine
Hanna M Hieromnimon, James Dolezal, Kristina Doytcheva, et al.
Kidney International
|
May 18, 2019
The motor protein Myo1c regulates transforming growth factor-β-signaling and fibrosis in podocytes
Ehtesham Arif, Ashish K Solanki, Pankaj Srivastava, et al.
Leukemia
|
February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Blood Advances
|
April 15, 2026
Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic Leukemia
Ruth W Wang'ondu, John A Kairalla, Mary Shago, et al.
Leukemia
|
April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Pediatric Blood & Cancer
|
September 9, 2022
Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group
Caitlin W Elgarten, Joel C Thompson, Anne Angiolillo, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 88) with videos related to
Sort By:
Page
of 9
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
April 28, 2021
Targeting myosin 1c inhibits murine hepatic fibrogenesis
Ehtesham Arif, Cindy Wang, Marzena K Swiderska-Syn, et al.
Ejhaem
|
August 21, 2023
SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731
Caitlin W Elgarten, John A Kairalla, Joel C Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2020
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Sumit Gupta, Cindy Wang, Elizabeth A Raetz, et al.
Pediatric Blood & Cancer
|
June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Genome Medicine
|
August 8, 2025
Building digital histology models of transcriptional tumor programs with generative deep learning for pathology-based precision medicine
Hanna M Hieromnimon, James Dolezal, Kristina Doytcheva, et al.
Kidney International
|
May 18, 2019
The motor protein Myo1c regulates transforming growth factor-β-signaling and fibrosis in podocytes
Ehtesham Arif, Ashish K Solanki, Pankaj Srivastava, et al.
Leukemia
|
February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Blood Advances
|
April 15, 2026
Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic Leukemia
Ruth W Wang'ondu, John A Kairalla, Mary Shago, et al.
Leukemia
|
April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Pediatric Blood & Cancer
|
September 9, 2022
Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group
Caitlin W Elgarten, Joel C Thompson, Anne Angiolillo, et al.
Page
of 9